Agglomeration Inhibition (tm) Changes in Absorptive Hypercalciuria Patients after Taking a New Slow-release Potassium Phosphate Preparation (Urophos-K).
- Author:
Young Gon KIM
1
Author Information
1. Department of Urology, Chonbuk National university, Medical School, ChonJu,Korea.
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords:
Urophos-k;
Agglomeration inhibition([tm]);
Absorptive hypercalciuria
- MeSH:
Citric Acid;
Diet;
Humans;
Hypercalciuria*;
Potassium*;
Prospective Studies;
Tablets
- From:Korean Journal of Urology
1995;36(9):939-943
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A new slow-release potassium phosphate preparation (Urophos-K), designed to minimize gastrointestinal side effects and avoid sodium-induced calciuria was tested in stone-formers with absorptive hypercalciuria(AH). In a prospective, randomized, double-blind tria1, 17 patients with AH received either Urophos-K (155mg P, 8 mEq K per tablet) 4 tablets twice daily or an identical placebo. Subjects were studied during a 4-day period in the hospital while consuming a constant metabolic diet containing 400mg Ca, 100meq Na, 800mg P/day before and after 3 months of treatment. The parameter of agglomeration inhibition ([h]) increased from 78.3+/-28.1 to 133.3+/-46.2 min4, consistent with the inhibitory action of citrate and pyrophosphate. Treatment with Urophos- K reduces urinary stone-forming potential.
